20 results about "Macrolide Antibiotics" patented technology

According to the scheme, the invention provides the recombinant macrolide enzyme as well as the preparation method and the application thereof, the amino acid sequence of the recombinant macrolide enzyme is as shown in SEQ ID NO.1, and the recombinant macrolide enzyme is derived from an EreC esterase family of enterobacter hormaechei and is obtained through site-specific mutagenesis; the mutation sites are as follows: glutamic acid at the 44th site is mutated into asparagine, tyrosine at the 55th site is mutated into proline, proline at the 76th site is mutated into arginine, phenylalanine at the 153rd site is mutated into alanine, and serine at the 219th site is mutated into glutamic acid. The method is expected to remove macrolide antibiotic pollution, and has good economic benefits and practical values.

According to the scheme, the recombinant macrolide enzyme and the preparation method and application thereof are provided, the amino acid sequence of the recombinant macrolide enzyme is shown as SEQ ID NO.1, and the recombinant macrolide enzyme is obtained by site-directed mutagenesis of an erythromycin esterase family protein sequence derived from enterobacter hormaechei; the mutation sites are as follows: the 44 glutamic acid is mutated into asparagine, the 55 tyrosine is mutated into proline, the 153 proline is mutated into alanine, and the 219 serine is mutated into glutamic acid, so that the specific macrolide lactonase which is efficient, stable, easy to prepare on a large scale and more suitable for environmental requirements is prepared, and macrolide antibiotic pollution is removed; and the method has good economic benefits and practical values.

The application discloses a preparation method and application of a cobalt monatomic doped strontium titanate composite material, and belongs to the field of water treatment. The cobalt doped strontium titanate composite catalytic material is composed of a cobalt metal doped strontium titanate material. A preparation process uses tetrabutyl titanate and a nitrate as reactants, ethylene glycol and water as solvents, and prepares strontium titanate (SrTiO3: STO) through a hydrothermal method. Then, cobalt monatomic atoms are doped into the strontium titanate through cobalt chloride (a cobalt source) by using an electrostatic adsorption method, so as to form cobalt doped strontium titanate (Co-STO). The material can efficiently activate an oxidant peracetic acid and rapidly degrade various antibiotic pollutants, and especially performs well in degrading quinolone, tetracycline and macrolide antibiotics. The catalytic material has the advantages of low cost, renewability and environmental protection, and is very suitable for being applied to a deep treatment process of pharmaceutical wastewater.

The invention relates to a method for analyzing pollutants in hospital wastewater based on liquid chromatography-high resolution mass spectrometry. The method comprises the following steps: S1, enriching pollutants in hospital wastewater through solid-phase extraction of four specific solid-phase extraction columns, and then analyzing and detecting a liquid to be detected through a specific chromatographic column, a specific liquid chromatography and a high-resolution mass spectrometry which are connected in series; the identification of various pollutants (medicines and metabolites thereof) in the hospital wastewater is realized, so that a data basis is provided for subsequent fingerprint analysis. Specifically, the analysis method provided by the invention can identify 34 kinds of substances, including sulfonamide antibiotics, macrolide antibiotics, cephalosporin antibiotics, quinolone antibiotics, beta-lactam antibiotics, aminoglycoside antibiotics and carbamazepine and metabolites thereof.

A new class of dimeric 2-aminoimidazole (2-AI) compounds that potentiate macrolide antibiotics against A. baumannii. A parent dimer lowers the MIC of clarithromycin (CLR) from 32 μg / mL to 1 μg / mL at a concentration of 7.5 μM (3.4 μg / mL), while a structure activity relationship (SAR) study on the dimeric 2-AI scaffold resulted in the identification of several compounds with increased activity. Substitution of fluorine on a central phenyl ring resulted in the most potent activity, with the lead compound, containing a fluorine ortho to each of the 2-AIs, that lowered the CLR MIC to 2 μg / mL against AB5075 at 1.5 μM (0.72 μg / mL), exceeding the activity of both the parent dimer and the lead aryl-2-AI. Furthermore, these dimeric 2-AI analogs exhibit favorably low mammalian cell toxicity.

The application discloses a synergistic bactericidal composition, comprising the following components: a toona sinensis extract: 16-2048 mu g / mL; a macrolide antibiotic: 0.0625-4096 mu g / mL; the bacteria are staphylococcus aureus or methicillin-resistant staphylococcus aureus, and the macrolide antibiotic is erythromycin or azithromycin. The application further discloses a use of the synergistic bactericidal composition in preparation of a medicine for treating skin and soft tissue infections. The composition provided by the application can convert the traditional macrolide antibiotics such as erythromycin and azithromycin which only have a bacteriostatic effect into a preparation which has clear bactericidal activity on staphylococcus aureus and drug-resistant strains thereof. After the toona sinensis extract is combined with the antibiotic, a synergistic effect is exhibited, and the concentration of the toona sinensis extract and the antibiotic required when the toona sinensis extract and the antibiotic are used alone can be greatly reduced.

This invention discloses a screening and detection method for antibiotic residues in organic fertilizers, relating to the field of trace residue detection. The detection method includes the following steps: S1, mixing the organic fertilizer sample with a buffer solution to obtain an extract; S2, adding a divalent calcium ion compound to the extract, mixing well, allowing it to stand, centrifuging, discarding the supernatant, and collecting the precipitate; S3, adding an alkaline releasing agent to the precipitate to dissolve it, centrifuging, collecting the supernatant, and obtaining a release solution; S4, reacting the release solution with a colorimetric reagent, measuring the visible light absorbance, and calculating the antibiotic content based on a standard curve. This method not only completely avoids the destruction of antibiotics by strong acids but also transforms humic acid from an interfering substance into an enrichment tool, thereby significantly improving the extraction rate. It is simple to operate and low in cost, thus providing a novel solution for the detection of macrolide antibiotic residues in organic fertilizers.

The invention relates to a transcription factor-based cell-free biosensor and an application thereof in water environment antibiotic detection. Firstly, a cell-free biosensor containing TetR or MphR is constructed, the cell-free biosensor comprises a DNA template, a transcription factor TetR or MphR, RNA polymerase and a DFHBI-1T fluorescent probe, the DNA template comprises a reporter gene capable of being combined with the fluorescent probe, and an operon corresponding to the transcription factor TetR or MphR is arranged on the upstream of the reporter gene; the biosensor can respond to tetracycline or macrolide antibiotics, and further, the content of the antibiotics can be measured according to the change of fluorescence intensity in a cell-free biosensor system. The invention provides the cell-free biosensor with high sensitivity and high stability, and the biosensor can realize high-efficiency detection under different water body conditions and realize stronger environmental adaptability.

The invention belongs to the technical field of biological detection, genotype detection of a mutation site of Bordetella pertussis 23S rRNA A2047G is realized based on a PCR-melting curve method, and then macrolide antibiotic resistant Bordetella pertussis is detected, and the following technical scheme is adopted: the detection kit for the macrolide antibiotic resistant Bordetella pertussis has the advantages that the genotype of the mutation site of the Bordetella pertussis 23S rRNA A2047G mutation site is detected; the kit comprises a reaction solution, a detection solution, a sensitive positive control, a drug-resistant positive control and a blank control. The detection method comprises the following steps: S1, taking a bordetella pertussis DNA sample as a template, simultaneously using sensitive positive control, drug-resistant positive control and blank control, and using the macrolide antibiotic drug-resistant bordetella pertussis detection kit in the patent for detection; and S2, data processing: after the reaction is finished, performing result judgment through a melting curve of the sample.

The present invention refers to an in vitro method for the diagnosis of a Mycoplasma pneumoniae infection and / or for the differential diagnosis between a Mycoplasma pneumoniae pneumonia and other bacterial or viral pneumonias and / or for assessing whether to treat a patient suffering from pneumonia with a macrolide antibiotic.

The invention provides a hybridoma cell strain CLA-4D3 capable of generating an anti-clarithromycin monoclonal antibody and application of the hybridoma cell strain CLA-4D3, and belongs to the technical field of monoclonal antibody preparation. The hybridoma cell strain CLA-4D3 provided by the invention is preserved in the China Center for Type Culture Collection on August 1, 2025, and the preservation number of the hybridoma cell strain CLA-4D3 is CCTCC (China Center for Type Culture Collection) NO: C2025232. The anti-clarithromycin monoclonal antibody is high in titer, the subtype of the anti-clarithromycin monoclonal antibody is IgG1, the semi-inhibition ratio IC50 of the anti-clarithromycin monoclonal antibody to clarithromycin is 1.52 [mu] g / L, the cross reaction rate of the anti-clarithromycin monoclonal antibody to clarithromycin is 100.00%, and the anti-clarithromycin monoclonal antibody has a good cross reaction with structural analogues. The anti-clarithromycin monoclonal antibody generated by the hybridoma cell strain CLA-4D3 disclosed by the invention can realize the purpose of rapidly and sensitively detecting 14-ring macrolide antibiotics such as clarithromycin, erythromycin and roxithromycin in food and environment.

The application discloses a strain of macrolide antibiotic high-efficiency degradation fungus Trichoderma asperellum TS7-1 and application thereof, and belongs to the technical field of microorganisms. The preservation number of the Trichoderma asperellum TS7-1 is CGMCC No.41372. The strain Trichoderma asperellum TS7-1 (CGMCC No.41372) provided by the application has high-efficiency degradation capacity for various macrolide antibiotics (erythromycin, roxithromycin and azithromycin), and the removal rates of the three antibiotics are all above 85% within 36 hours. The high-concentration antibiotic tolerance, degradation rate and degradation spectrum of the Trichoderma asperellum TS7-1 are obviously superior to those of other strains in the prior art. The Trichoderma asperellum TS7-1 is directly separated from a natural soil body without antibiotic pollution, has no hidden danger of animal and plant pathogenicity, and has no microbial toxicity to degradation products of the macrolide antibiotics, so that secondary pollution is avoided, and excellent environmental safety is achieved.

The invention discloses a defect engineering modified composite catalyst as well as a preparation method and application thereof, and belongs to the technical field of environmental material preparation. The preparation method comprises the following steps: (1) performing reduction heat treatment on a titanium silicalite molecular sieve in a hydrogen-containing inert atmosphere to obtain an oxygen vacancy-containing titanium silicalite molecular sieve; and (2) stirring and mixing the oxygen vacancy-containing titanium silicalite molecular sieve solution and the ferric salt solution, centrifuging the product, washing with water, washing with alcohol, and drying to obtain the defect engineering modified composite catalyst. The titanium silicalite molecular sieve is firstly subjected to reduction heat treatment to construct oxygen vacancies, then iron ions are specifically anchored on the oxygen vacancies, the composite catalyst with excellent photocatalytic activity and stability is prepared, the composite catalyst is used for treating macrolide antibiotics in water, and efficient degradation of antibiotic wastewater is achieved.

The invention discloses a preparation method of a tGmR bacterial sensor, a product of the tGmR bacterial sensor and application of the tGmR bacterial sensor. The tGmR bacterial sensor contains recombinant plasmids pET-mpR-tetR-mpA-tetM. The biosensor disclosed by the invention can realize real-time, low-cost and biological related detection on chemical pollutants; the genetic stability is better; resistance genes tetM and mpphA are introduced, so that the detection sensitivity and the tolerance to high-concentration antibiotics are improved; on the basis of bacteria, the bio-available concentration of tetracycline and macrolide antibiotics can be detected at the same time; the detection limit of the tGmR bacterial sensor on tetracycline is 11.1 [mu] g / L, the LOD of the tGmR bacterial sensor on erythromycin is 16.3 [mu] g / L, and in addition, the tGmR bacterial sensor can simultaneously detect the erythromycin with the maximum of 125 [mu] g / L and the tetracycline with the maximum of 250 [mu]

This invention discloses a magnetic organic polymer for the enrichment and extraction of macrolide antibiotics, its preparation, and its application. The magnetic organic polymer has a core-shell structure, with magnetic Fe3O4 nanoparticles as the core and a Tb-PDAN organic polymer formed by the reaction of trimesin and terephthalonitrile as the shell. This magnetic organic polymer can be used as an adsorbent for the enrichment and extraction of macrolide antibiotics in water, enabling qualitative and / or quantitative detection of macrolide antibiotics. The magnetic organic polymer of this invention can simultaneously, rapidly, and efficiently extract 16 macrolide antibiotics from water and is reusable, making it of significant importance for advancing the monitoring of macrolide antibiotics in water.

The invention discloses a coding gene of carbamoyltransferase VtdB and an application of the coding gene. The amino acid sequence of the carbamoyltransferase VtdB is as shown in SEQ ID NO.2, and the nucleotide sequence of the coding gene of the carbamoyltransferase VtdB is as shown in SEQ ID NO.1. According to the invention, targeted blocking is carried out on the carbamoyltransferase gene vtdB, so that the obtained gene blocking mutant strain does not produce the melanocidin A any more, and meanwhile, the melanocidin B and the melanocidin X can be produced. Then, the carbamoyltransferase VtdB is used as a catalyst, and the carbamoyltransferase VtdB can be used for catalyzing the melanocidin B and carbamoyl phosphoric acid in vitro to synthesize the melanocidin A. Functional identification of the vtdB has practical guiding significance on large-scale production of macrolide antibiotics, namely the melanocidin A, the melanocidin B and the melanocidin X, and the vtdB can be applied to the fields of biology, medicine, fine chemical engineering, agriculture and the like.

The invention discloses a synergistic bactericidal composition which comprises the following components: 16 g / mL-2048 g / mL of cortex albiziae extract, 10 g / mL-20 g / mL of plant extract, 10 g / mL-20. The content of the macrolide antibiotics is 0.0625 g / mL to 4096 g / mL; the bacteria are staphylococcus aureus or methicillin-resistant staphylococcus aureus, and the macrolide antibiotics are erythromycin or azithromycin. The invention also discloses application of the synergistic bactericidal composition in preparation of medicines for treating skin and soft tissue infection. According to the composition provided by the invention, macrolide antibiotics, such as erythromycin and azithromycin, which only have a bacteriostatic effect traditionally can be converted into preparations which have definite bactericidal activity on staphylococcus aureus and drug-resistant strains thereof. After the cortex albiziae extract and the antibiotics are combined for use, an extremely strong synergistic effect is shown, and the concentrations required when the cortex albiziae extract and the antibiotics take effect independently can be greatly reduced.

Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.

The application discloses a method for degrading macrolide antibiotic wastewater by using a biochar composite catalyst. ‑ Free radicals and SO4 ·‑ Free radicals, which can act on the lactone ring and glycosidic bond of the sugar group connected to the macrolide antibiotic, and then degrade the antibiotic. The degradation method for the macrolide antibiotic wastewater provided by the application can treat low-concentration antibiotic pharmaceutical wastewater, and has simple process and good degradation effect; the biochar composite catalyst has low corrosion and can adapt to complex water quality changes, is green and safe, and can be recycled multiple times, thereby providing a new method for degrading macrolide antibiotics in low-concentration antibiotic wastewater, realizing solid waste resource utilization, and having wide application prospect.

The invention discloses a synergistic bactericidal composition, which comprises the following components: 256g / mL to 8192 g / mL of poplar bud flavin; the content of the macrolide antibiotics is 0.125 g / mL to 4096 g / mL; the bacteria are staphylococcus aureus or methicillin-resistant staphylococcus aureus, and the macrolide antibiotics are erythromycin or azithromycin. The invention also discloses an application of the synergistic bactericidal composition in preparation of a medicine for treating infection caused by staphylococcus aureus or methicillin-resistant staphylococcus aureus. According to the composition provided by the invention, macrolide antibiotics, such as erythromycin and azithromycin, which only have a bacteriostatic effect on staphylococcus aureus and drug-resistant strains thereof traditionally can be converted into preparations with definite bactericidal activity. After the poplatin and the antibiotics are combined for use, a remarkable synergistic effect is shown, and the concentration of the antibiotics required for realizing the sterilization effect can be greatly reduced.